Analysis of the legal issues with the current IP system for regulated market authorisations for pharmaceutical products, as well as its economic effects.

It has been a long standing ambition of the Commission to improve the patent system in Europe, to ensure incentives to innovate in a single European market and support EU firms’ global competitiveness. For products subject to regulated market authorisations, such as pharmaceuticals, compulsory and lengthy testing and clinical tries that products require prior to obtaining regulatory marketing approval reduces the effective patent protection. To offset this loss, Supplementary Protection Certificate (SPC) grants an extension of up to five years to the term of a patent right (of twenty years). This SPC protection is currently being evaluated in terms of its fit to a changing global trade and innovation model.

This event will look at both the legal issues with the current IP system for regulated market authorisations for pharmaceutical products, as well as the economic effects which the current system may have had. While reviewing any changes in the global innovation structure of the pharmaceutical industry, we will discuss possible re-calibrations.

This event will be livestreamed at 13:00 CET. There is no need to register for the livestream.

Register for this event.

SCHEDULE